# Risk-Benefit Composition Validation

**Status:** ğŸ”„ Validation In Progress  
**Scope:** Deterministic logic validation for Risk-Benefit Composition  
**Date:** January 2025

## ğŸ“ Directory Structure

```
risk_benefit_validation/
â”œâ”€â”€ README.md                          # This file
â”œâ”€â”€ docs/                              # Documentation
â”‚   â””â”€â”€ VALIDATION_PLAN.md             # Detailed validation plan
â”œâ”€â”€ scripts/                           # Validation scripts
â”‚   â””â”€â”€ validate_composition.py        # Main validation script
â”œâ”€â”€ data/                              # Test data
â”‚   â””â”€â”€ synthetic_cases.json           # 15 clinically-grounded cases
â””â”€â”€ reports/                           # Validation reports
    â””â”€â”€ composition_report.json        # Generated receipt
```

## ğŸ¯ What This Validates

**The Risk-Benefit Composition Policy:**
- HIGH toxicity â†’ Hard veto (composite = 0, AVOID)
- MODERATE toxicity â†’ Penalized (composite = efficacy Ã— adjustment_factor)
- LOW toxicity â†’ Full efficacy preserved
- Missing PGx â†’ Flagged but not blocking

## ğŸš€ Quick Start

```bash
cd risk_benefit_validation
python3 scripts/validate_composition.py
```

## ğŸ“Š Synthetic Test Cases (N=15)

| Group | Cases | What It Tests |
|-------|-------|---------------|
| **A: HIGH Toxicity** | 3 | Hard veto (DPYD *2A, *13, TPMT *3A/*3A) |
| **B: MODERATE Toxicity** | 4 | Dose adjustment penalty |
| **C: LOW Toxicity** | 5 | Full efficacy preserved |
| **D: Edge Cases** | 3 | Missing PGx, low efficacy, WT variants |

## âš ï¸ Transparency Notice

**What This PROVES:**
- âœ… Composition logic is deterministically correct
- âœ… All toxicity tiers handled as specified
- âœ… Edge cases (missing data, WT variants) handled gracefully
- âœ… Rankings reflect risk-benefit priority

**What This DOES NOT PROVE:**
- âŒ The policy improves patient outcomes
- âŒ The weights are optimal
- âŒ The system generalizes to unseen patients
- âŒ The integration predicts clinical response

## ğŸ“š CPIC References

- **DPYD**: Amstutz et al. Clin Pharmacol Ther. 2018;103(2):210-216
- **TPMT**: Relling et al. Clin Pharmacol Ther. 2019;105(5):1095-1105
- **UGT1A1**: Gammal et al. Clin Pharmacol Ther. 2016;99(4):363-369
- **CYP2D6**: Goetz et al. Clin Pharmacol Ther. 2018;103(5):770-777

## ğŸ”— Related Validations

- **PGx Toxicity Detection**: `dosing_guidance_validation/` (100% sensitivity/specificity)
- **Drug Efficacy (S/P/E)**: `VALIDATED_CLAIMS_LEDGER.md` (100% top-5 accuracy)
- **Mechanism Fit**: `VALIDATED_CLAIMS_LEDGER.md` (0.983 mean for DDR-high)

---

**Last Updated:** January 2025  
**Author:** Zo (Agent)  
**Status:** Validation Pending

